← Browse by Condition
Medical Condition
macular degeneration
Total Trials
4
Recruiting Now
4
Trial Phases
Phase 1, Phase 2, Phase 2, EARLY_Phase 1
ClinicalMetric tracks all active clinical trials for macular degeneration sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.
- Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
- Phase 1–4 studies from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary available for every trial listing
Frequently Asked Questions — macular degeneration Clinical Trials
How many clinical trials are currently recruiting for macular degeneration?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for macular degeneration, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for macular degeneration?
macular degeneration research spans Phase 1 (3 trials), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a macular degeneration clinical trial?
Eligibility criteria for macular degeneration trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 3
Phase 2 2
Top Sponsors
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT06394232 Phase 1, Phase 2
Recruiting
Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.
Enrollment
54 pts
Location
India
Sponsor
Eyestem Research Pvt. Ltd.
NCT06635148 Phase 2
Recruiting
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Enrollment
274 pts
Location
United States, Austr...
Sponsor
Janssen Research & Development...
NCT04008121 EARLY_Phase 1
Recruiting
Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
Enrollment
10 pts
Location
United States
Sponsor
MediBeacon
NCT05147701 Phase 1
Recruiting
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for NAION
Enrollment
20 pts
Location
Antigua and Barbuda,...
Sponsor
The Foundation for Orthopaedic...
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology